Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.